Concepedia
Statistics
Publications
13
Citations
1.1K
H-Index
12
Active since
2018
Affiliations
Moffitt Cancer Center(Current)
University of South Florida
Johns Hopkins University
Assistance Publique – Hôpitaux de Paris
The University of Texas MD Anderson Cancer Center
Amy F. McLemore is an author at Moffitt Cancer Center specializing in myelodysplastic syndromes, medicine, and molecular oncology.
Publications per year
2018–2025
Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes
David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero et al. · Journal of Clinical Oncology · 2021 · 460 citations · Full text
Medicine, Oncology, Pharmacology +5
<i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
David A. Sallman, Amy F. McLemore, Amy L. Aldrich et al. · Blood · 2020 · 188 citations · Full text
Medicine, Hematology, Molecular Genetics +13
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero et al. · Blood · 2019 · 73 citations
Medicine, Oncology, Pharmacotherapy +16
Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
David A. Sallman, Amy E. DeZern, David P. Steensma et al. · Blood · 2018 · 67 citations
Medicine, Oncology, Pharmacology +17
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study
Ashley A. Basiorka, Kathy L. McGraw, Farnoosh Abbas‐Aghababazadeh et al. · The Lancet Haematology · 2018 · 57 citations · Full text
Medicine, Hematology, Pathology +10
1–5 of 13